This mechanism distinguishes TE‐1146 from lenalidomide and daratumumab: lenalidomide alone cannot easily enter cells, whereas daratumumab relies on Fc‐dependent effector functions to kill CD38‐expressing tumor cells. The gene discussed is CD38; the disease is neoplasm.